Data gathered: June 24
AI Stock Analysis - Verve Therapeutics (VERV)
Analysis generated March 26, 2025. Powered by Chat GPT.
Verve Therapeutics is a biotechnology company that leverages cutting-edge technology to develop therapies focused on cardiovascular disease management. With their emphasis on gene editing, Verve Therapeutics aims to transform the treatment paradigm, providing lasting solutions through innovative approaches. Their strategies are built around translating scientific advancements into viable therapeutic applications.
Stock Alerts - Verve Therapeutics (VERV)
 |
Verve Therapeutics | June 17 Price is up by 75.4% in the last 24h. |
|
Verve Therapeutics | June 6 Price is up by 8.2% in the last 24h. |
|
Verve Therapeutics | June 5 Price is up by 11.2% in the last 24h. |
|
Verve Therapeutics | June 4 Price is up by 7.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Verve Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 18 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 400 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,535 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,141 | Sign up | Sign up | Sign up |
| Twitter Mentions | 194 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 71 | Sign up | Sign up | Sign up |
| Linkedin Employees | 311 | Sign up | Sign up | Sign up |
About Verve Therapeutics
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
| Price | $11.11 |
| Target Price | Sign up |
| Volume | 5,510,000 |
| Market Cap | $988M |
| Year Range | $2.97 - $11.38 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
What is Lifesci Capital’s Estimate for VERV Q2 Earnings?June 20 - ETF Daily News |
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This WeekJune 20 - Yahoo Entertainment |
|
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of ShareholdersJune 20 - GlobeNewswire |
|
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)June 20 - GlobeNewswire |
|
|
Jefferies Financial Group Downgrades Verve Therapeutics (NASDAQ:VERV) to HoldJune 19 - ETF Daily News |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, COLB on Behalf of ShareholdersJune 19 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 33M | 0 | 0 | -31M | -37M | -0.350 |
| Q4 '24 | 13M | 1.7M | 11M | -50M | -54M | -0.580 |
| Q3 '24 | 6.9M | 1.8M | 5.1M | -50M | -55M | -0.590 |
| Q2 '24 | 6.7M | 1.7M | 5M | -50M | -57M | -0.590 |
| Q1 '24 | 5.7M | 1.6M | 4.1M | -49M | -55M | -0.590 |
Insider Transactions View All
| Lister Troy filed to sell 6,952 shares at $4.2. April 3 '25 |
| Dorval Allison filed to sell 13,280 shares at $4.2. April 3 '25 |
| Politi Jason filed to sell 14,226 shares at $4.2. April 3 '25 |
| Ashe Andrew D. filed to sell 348,828 shares at $4.2. April 3 '25 |
| Nickerson Joan filed to sell 17,420 shares at $4.2. April 3 '25 |
Similar companies
Read more about Verve Therapeutics (VERV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Verve Therapeutics?
The Market Cap of Verve Therapeutics is $988M.
What is the current stock price of Verve Therapeutics?
Currently, the price of one share of Verve Therapeutics stock is $11.11.
How can I analyze the VERV stock price chart for investment decisions?
The VERV stock price chart above provides a comprehensive visual representation of Verve Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Verve Therapeutics shares. Our platform offers an up-to-date VERV stock price chart, along with technical data analysis and alternative data insights.
Does VERV offer dividends to its shareholders?
As of our latest update, Verve Therapeutics (VERV) does not offer dividends to its shareholders. Investors interested in Verve Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Verve Therapeutics?
Some of the similar stocks of Verve Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.